← Back to Company DatabaseVisit Website
Nucleai
Spatial biology AI platform for precision oncology biomarker discovery.
Series BTel Aviv, IsraelFounded 2017
About
Nucleai develops AI-powered spatial biology analytics that help pharmaceutical companies discover and validate cancer biomarkers from tissue images. The platform combines computer vision and spatial analysis to understand the tumor microenvironment at single-cell resolution. The Israeli company partners with leading biopharma companies to accelerate cancer drug development.
Total Funding
$50MKey Product
Nucleai spatial biology AI analytics platformGeography
EuropeKey Investors
DebiopharmElyptaCathay Innovation
Focus Areas
AI / Machine LearningDrug DiscoveryDiagnostics
Technology
AI / Machine LearningImaging / Radiology
Cancer Types
Pan-cancer
Last updated: Feb 4, 2026